Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice

Nutrition Research

Volumn 32, Issue 11, 2012, Pages 873-883

  Park, Jin Hee ^a   Davis, Keith R ^b   Lee, Gunsup ^c   Jung, Manyong ^d   Jung, Yuchul ^d   Park, Jungan ^d   Yi, Sang Yeop ^e   Lee, Myung Ah ^f   Lee, Sukchan ^d   Yeom, Chang Hwan ^g   Kim, Jin ^a  

^a The Catholic University of Korea   (South Korea)

^b Mitchell Memorial Cancer Center   (United States)

^c Korea Research Institute of Ships and Ocean Engineering   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Catholic Kwandong University   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g U Cell Clinic   (South Korea)

Author keywords

Alleviatory effect; Ascorbic acid; Combinational treatment; Cytotoxicity; Paclitaxel

Indexed keywords

ASCORBIC ACID; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CELL DIVISION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETICULOCYTOSIS; RETICULOSIS; SARCOMA; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCORBIC ACID; BLOOD CELL COUNT; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; HEMOGLOBINS; HUMANS; MICE; MICE, INBRED BALB C; PACLITAXEL; SARCOMA 180; VITAMINS;

MUS;

EID: 84870063021     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.09.011     Document Type: Article

References (40)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.
2. Treatment of advanced non-small-cell lung cancer: a review of current randomizedclinical trials and an examination of emerging therapies. Cancer Control 2002, 8:326-336.
3. Sarosy G., Reed E. Taxol dose intensification and its clinical implications. J Natl Med Assoc 1993, 85:427-431.
4. Mekhail T.M., Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002, 3:755-766.
5. Alexandre J., Hu Y., Lu W., Pelicano H., Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 2007, 67:3512-3517.
6. Ferlini C., Cicchillitti L., Raspaglio G., Bartollino S., Cimitan S., Bertucci C., et al. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res 2009, 69:6906-6914.
7. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). SeminOncol 1993, 20:1-15.
8. Hardy D., Cormier J.N., Xing Y., Liu C.C., Xia R., Du X.L. Chemotherapy-Associated Toxicity in a Large Cohort of Elderly Patients with Non-small Cell Lung Cancer. J Thorac Oncol 2010, 5:90-98.
9. Gonzalez M.J., Miranda-Massari J.R., Mora E.M., Guzman A., Riordan N.H., Riordan H.D., et al. Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther 2005, 4:32-44.
10. Moertel C.G., Fleming T.R., Creagan E.T., Rubin J., O'Connell M.J., Ames M.M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985, 312:137-141.
11. Cullen J.J. Ascorbate induces autophagy in pancreatic cancer. Autophagy 2010, 6:421-422.
12. Agus D.B., Vera J.C., Golde D.W. Stromal Cell Oxidation: A Mechanism by Which Tumors Obtain Vitamin C. Cancer Res 1999, 59:4555-4558.
13. Drisko J.A., Chapman J., Hunter V.J. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 2003, 22:118-123.
14. Lamson D.W., Brignall M.S. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 1999, 4:304-329.
15. Prasad K.N., Kumar A., Kochupillai V., Cole W.C. High Doses of Multiple Antioxidant Vitamins: Essential Ingredients in Improving the Efficacy of Standard Cancer Therapy. J Am CollNutr 1999, 18:13-25.
16. Fromberg A., Gutsch D., Schulze D., Vollbracht C., Weiss G., Czubayko F., et al. Ascorbate exerts anti-poliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 2011, 67:1157-1166.
17. Chen Q., Espey M.G., Sun A.Y., Pooput C., Kirk K.L., Krishna M.C., et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008, 105:11105-11109.
18. Chen Q., Espey M.G., Sun A.Y., Lee J.H., Krishna M.C., Shacter E., et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007, 104:8749-8754.
19. Roomi M.W., Roomi N.W., Kalinovsky T., Rath M., Niedzwiecki A. Marked inhibition of growth and invasive parameters of head and neck squamous carcinoma FaDu by a nutrient mixture. Integr Cancer Ther 2009, 8:168-176.
20. Blasiak J., Kowalik J. Protective action of vitamin C against DNA damage induced by selenium-cisplatin conjugate. Acta Biochim Pol 2001, 48:233-240.
21. Yeom C.H., Lee G., Park J.H., Yu J., Park S., Yi S.Y., et al. High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 2009, 7:70.
22. Fotakis G., Timbrell J.A. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 2006, 160:171-177.
23. Lasnier E., Mario N., Boque M.C., You S.N., Vaubourdolle M. Evaluation of the clinical chemistry analyser Olympus AU400. Clin Chem Lab Med 2000, 38:1043-1049.
24. Geistanger A., Arends S., Berding C., Hoshino T., Jeppsson J.O., Little R., et al. Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan, and Sweden. Clin Chem 2008, 54:1379-1385.
25. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
26. Churin A.A., Gol'dberg V.E., Karpova G.V., Voronova O.L., Feodorova E.P., Kolotova O.V., et al. Reaction of bone marrow hematopoiesis to the toxic effect of paclitaxel. Bull ExpBiol Med 2008, 145:213-217.
27. Sekine I., Nishiwaki Y., Watanabe K., Yoneda S., Saijo N. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 1996, 2:941-945.
28. Latvala J., Parkkila S., Niemela O. Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells. Alcohol ClinExp Res 2004, 28:619-624.
29. Dukas K., Sarfati P., Vaysse N., Pradayrol L. Quantitation of changes in the expression of multiple genes by simultaneous polymerase chain reaction. Anal Biochem 1993, 215:66-72.
30. Wei W., Zheng-zhong B., Yong-jie W., Qing-wu Z., Ya-lin M. Bioeffects of low-frequency ultrasonic gene delivery and safety on cell membrane permeability control. J Ultrasound Med 2004, 23:1569-1582.
31. Mazumdar U.K., Gupta M., Maiti S., Mukherjee D. Antitumor activity of Hygrophilaspinosa on Ehrlich ascites carcinoma and sarcoma-180 induced mice. Indian J ExpBiol 1997, 35:473-477.
32. Shinomiya N., Tsuru S., Tsugita M., Takemura T., Katsura Y., Nomoto K. Differential function of polymorphonuclear leukocytes between in vivo and in vitro in tumor-bearing mice. J Clin Lab Immunol 1990, 33:61-68.
33. Gordon M.S. Managing anemia in the cancer patient: old problems, future solutions. Oncologist 2002, 7:331.
34. Kurbacher C.M., Wagner U., Kolster B., Andreotti P.E., Krebs D., Bruckner H.W. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 1996, 103:183-189.
35. Abdel-Latif M.M., Raouf A.A., Sabra K., Kelleher D., Reynolds J.V. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother 2005, 17:539-549.
36. Drisko J.A., Chapman J., Hunter V.J. The use of antioxidant therapies during chemotherapy. GynecolOncol 2003, 88:434-439.
37. Prasad K.N. Multiple Dietary Antioxidants Enhance the Efficacy of Standard and Experimental Cancer Therapies and Decrease Their Toxicity. Integr Cancer Ther 2004, 3:310-322.
38. Block K.I., Koch A.C., Mead M.N., Tothy P.K., Newman R.A., Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008, 123:1227-1239.
39. Ullah M.F., Khan H.Y., Zubair H., Shamim U., Hadi S.M. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother Pharmacol 2011, 67:103-110.
40. Lee C.K., Son S.H., Park K.K., Park J.H., Lim S.S., Kim S.H., et al. Licochalcone A Inhibits the Growth of Colon Carcinoma and Attenuates Cisplatin-Induced Toxicity without a Loss of Chemotherapeutic Efficacy in Mice. Basic Clin Pharmacol Toxicol 2008, 103:48-54.